Shares of Humacyte, Inc. (HUMA) soared 5.51% in pre-market trading on Wednesday, despite the biotechnology company reporting a wider net loss for the third quarter of 2024 compared to analysts' expectations.
Humacyte posted an operating loss of $30.23 million for Q3 2024, slightly higher than the consensus estimate of $29.7 million. The net loss for the quarter came in at $39.2 million or $0.33 per share, compared to Wall Street's expectations of a $30 million loss.
Despite the headline numbers missing estimates, investors appeared to be focusing on other factors, driving Humacyte's stock higher ahead of the market open. The company did not provide additional commentary in its earnings release to explain the pre-market surge, leaving investors to speculate on the reasons behind the positive stock movement.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。